BERLIN – The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) approved the proposal of the Executive Board and Supervisory Board to pay a dividend of EUR 0.22 per share for the 2025 fiscal year, up from EUR 0.17 in the previous year. The decision underscores the company's commitment to delivering value to its shareholders amid a robust financial performance.
Held as an in-person event adjacent to the company's Berlin headquarters, the meeting saw 55.37% of the share capital represented. Shareholders endorsed the actions of the Executive Board and Supervisory Board for the 2025 fiscal year and approved all agenda items by a large majority. The detailed voting results and the CEO's presentation are available on the company's website at https://www.ezag.com/investors/annual-general-meeting/.
Eckert & Ziegler SE, a leading specialist in isotope-related components for nuclear medicine and radiation therapy, employs over 1,000 people. The company provides a broad range of services and products for the radiopharmaceutical industry, from early development to contract manufacturing and distribution. Its shares are listed in the TecDAX index of Deutsche Börse.
The dividend increase signals confidence in the company's growth trajectory and its ability to generate sustainable returns. For a company operating in the critical field of nuclear medicine, this financial milestone underscores its stability and strategic focus on saving lives through innovative medical solutions.
